Exosome Market Technologies Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players

Exosome Technologies Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players research report Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector.

ReportsnReports adds new report Exosome Market Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players, explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine and cerebrospinal fluid as well as in in vitro cell culture.

These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right. Research within this area remains in the nascent stages, although a number of clinical trials have been registered within the field. Exosomes have several diverse therapeutic applications, largely centering on stem cell and gene therapy. Exosomes have been identified as endogenous carriers of RNA within the body, allowing for the intercellular transportation of genetic material to target cells.

Get Discount on Exosome Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1781607

As such, developers have worked to engineer exosomes for the delivery of therapeutic miRNA and siRNA-based gene therapies. As RNA is highly unstable within the body, a number of different biologic vector systems have been developed to enhance their transport within the circulation, including viruses and liposomes. Similarly, exosomes derived from stem cells have also been identified for their therapeutic applications, particularly in the treatment of cancer and cardiovascular disease. Exosome technologies offer several advantages over existing biologic-based drug delivery systems.

They have a long circulatory half-life as a result of their high stability and ability to avoid breakdown by the mononuclear phagocyte system and reticuloendothelial systems. Moreover, exosomes have several functional properties that favor their use in therapeutic delivery. Exosomes can be engineered to incorporate targeting ligands, allowing them to deliver cargo selectively to cells. Their small size allows them to penetrate the blood-brain barrier for the delivery of central nervous system therapies, whereas in cancer they can accumulate within the tumor via enhanced permeability and retention effects.
Finally, clinical trials have shown relatively large-scale production to be possible and indicate that exosome therapies can be safely administered to humans. Additionally, exosomes are being investigated for their potential as prognostic and diagnostic biomarkers for several different disease indications. Exosomes make good candidates for biomarker research because of two unique characteristics: their presence in various accessible bodily fluids, and their resemblance to their parent cells of origin. R&D in exosome technologies has increased markedly in recent years. This report provides detailed information on the various healthcare applications of exosomes, and assesses the pipeline, clinical trial and company landscapes.

Get a Copy of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1781607

• What are the features of the exosome lifecycle?
• How are therapeutic exosomes prepared?
• How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?
• Which companies are investing in exosome technologies?
• How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?
Reasons to buy
• Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector.
• Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies.
• Identify trends in interventional and observational clinical trials relevant to exosomes."

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Exosomes in Healthcare
2.1 Overview of Exosomes
2.2 Drug Delivery Systems
2.2.1 Modified Release Drug Delivery Systems
2.2.2 Targeted Drug Delivery Systems
2.2.3 Liposomes
2.2.4 Viruses
2.2.5 Exosomes
2.3 The Exosome Lifecycle
2.4 Exosomes in Biology
2.5 Exosomes in Medicine
2.5.1 Biomarkers
2.5.2 Vaccines
2.6 Exosomes as a Therapeutic Target
2.7 Exosomes as Drug Delivery Vehicles
2.8 Therapeutic Preparation of Exosomes
2.8.1 Isolation and Purification
2.8.2 Drug Loading
2.8.3 Characterization
2.8.4 Bioengineering
2.8.5 Biodistribution and In Vivo Studies
2.8.6 Advantages of Exosome Therapies
2.8.7 Disadvantages of Exosome Therapies
2.9 Exosomes in Therapeutic Research
2.9.1 Exosome Gene Therapies
2.9.2 Exosome in Stem Cell Therapy
2.10 Exosomes in Oncology
2.10.1 Immunotherapy
2.10.2 Gene Therapy
2.10.3 Drug Delivery
2.10.4 Biomarkers
2.11 Exosomes in CNS Disease
2.11.1 Tackling the Blood-Brain Barrier
2.11.2 Exosomes in CNS Drug Delivery
2.11.3 Gene Therapy
2.12 Exosomes in Other Diseases
2.12.1 Cardiovascular Disease
2.12.2 Metabolic Disease

Inquiry Before Buying this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1781607

3 Assessment of Pipeline Product Innovation
3.1 Overview
3.2 Exosome Pipeline by Stage of Development and Molecule Type
3.3 Pipeline by Molecular Target
3.4 Pipeline by Therapy Area and Indication
3.5 Pipeline Product Profiles
3.5.1 AB-126 - ArunA Biomedical Inc.
3.5.2 ALX-029 and ALX-102 - Alxerion Biotech
3.5.3 Biologics for Autism - Stem Cell Medicine Ltd
3.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc.
3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty
3.5.6 Biologic for Lysosomal Storage Disorder - Exerkine
3.5.7 Biologics for Prostate Cancer - Cells for Cells
3.5.8 CAP-2003 - Capricor Therapeutics Inc.
3.5.9 CAP-1002 - Capricor Therapeutics Inc.
3.5.10 CIL-15001 and CIL-15002 - Ciloa
3.5.11 ExoPr0 - ReNeuron Group Plc
3.5.12 MVAX-001 - MolecuVax Inc.
3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences
3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc.
3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd
3.5.16 TVC-201 and TVC-300 - Tavec Inc.

4 Assessment of Clinical Trial Landscape
4.1 Interventional Clinical Trials
4.1.1 Clinical Trials by Therapy Type
4.1.2 Clinical Trials by Therapy Area
4.1.3 Clinical Trials by Stage of Development
4.1.4 Clinical Trials by Start Date and Status
4.2 Observational Clinical Trials
4.2.1 Clinical Trials by Therapy Type
4.2.2 Clinical Trials by Therapy Area
4.2.3 Clinical Trials by Stage of Development
4.2.4 Clinical Trials by Start Date and Status
4.2.5 List of All Clinical Trials

5 Company Analysis and Positioning
5.1 Company Profiles
5.1.1 Capricor Therapeutics Inc.
5.1.2 Evox Therapeutics Ltd
5.1.3 ReNeuron Group Plc
5.1.4 Stem Cell Medicine Ltd
5.1.5 Tavec Inc.
5.1.6 Codiak Biosciences Inc.
5.1.7 Therapeutic Solutions International Inc.
5.1.8 ArunA Biomedical Inc.
5.1.9 Ciloa

Contact Info:
Name: Hrishikesh Patwardhan
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1781607-exosome-technologies-recent-surge-in-r-d-with-capricor-codiak-and-evox-therapeutics-among-key-players.html

Release ID: 448118